Product Pipeline

IND Code	Dosage Form	Indications	Development Location	Development Stage
S-1	Oral	Gastric cancer	US	Phase III
	Oral	Uterocervical cancer	Japan	Phase III
	Oral	Uterocervical cancer	Asia	Phase III
	Oral	Hepatocellular carcinoma	Japan	Phase III
	Oral	Renal cell carcinoma	Japan	Phase II
ABI-007	Injection	NSCLC	Japan	Filed
ABI-007	Injection	Gastric cancer	Japan	Filed
OVF	Buccal	Cancer pain	Japan	Phase III
TSU-68	Oral	Hepatocellular carcinoma	Japan	Phase III
	Oral	Hepatocellular carcinoma	Asia	Phase III
	Oral	Gastric cancer	Japan	Phase II
	Oral	Colorectal cancer	Asia	Phase II
	Oral	NSCLC	Japan	Phase I
TAS-102	Oral	Colorectal cancer	Japan	Phase II
TAS-102	Oral	Colorectal cancer	US	Phase I
TAS-106	Injection	Solid tumors	US	Phase I/II
ET-743	Injection	Malignant soft tissue sarcome	Japan	Phase I
TAS-115	Oral	Solid tumors	Japan	Phase I
YP-18	Injection	Peritonitis, intra-abdominal abscess, cholecystitis, cholangitis	Japan	Filed
YP-18	Injection	Febrile neutropenia	Japan	Phase III
TAC-201	Injection	Cedar pollen allergy	Japan	Phase II

As of March 31, 2012

[S-1] is an oral antimetabolite consisting of FT, CDHP, and Oxonic acid. FT is a pro-drug of 5FU, CDHP enhances efficacy by inhibiting degradation of 5FU, and Oxonic acid reduces digestive tract-related side effects.
[ABI-007] is a nanoparticle formulation of paclitaxel.
[OVF] is a transmucosal fentanyl tablet for the treatment of breakthrough cancer pain.
[TSU-68] is a low-molecular-weight anti-angiogenetic agent that inhibits receptor tyrosine kinase.
[TAS-102] is a novel combination antitumor agent, consisting of trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI). FTD induces DNA dysfunction through efficient incorporation into DNA, which leads to the inhibition of tumor growth. The TPI prevents degradation of FTD.
[TAS-106] is an antitumor ribonucleoside that inhibits RNA polymerase.
[ET-743] is a novel marine-derived antitumor agent isolated from the colonial tunicate Ecteinascidia turbinate. The drug binds to the minor groove of the DNA and induces apotosis.
[TAS-115] is a low-molecular-weight receptor tyrosine kinase inhibitor targeting MET and VEGFRs.
[YP-18] is a combination antibiotic consisting of the piperacillin and tazobactam.
[TAC-201] is a new recombinant T cell epitope consensus peptide for immunotherapy of Japanese cedar pollinosis.